A genetic “Minority Report”: How corporate DNA testing could put us at risk
By Benjamin Winterhalter,
Salon
| 01. 26. 2014
On Nov. 22, 2013, the FDA sent a now-infamous letter to the genetic
research startup 23andMe, ordering the company to stop marketing some of
its personal DNA testing kits. In its letter, the agency told 23andMe
that it was concerned about the possibility of erroneous test results,
about false positives and false negatives. The FDA warned that false
positives – for example, being told that one has a high risk of breast
cancer when really one doesn’t – might lead customers to seek expensive
testing or medical treatment that they don’t really need. False
negatives – which are just the opposite – might lead customers to ignore
serious health problems or deviate from a prescribed treatment regime.
The company had been out of contact with the FDA since May of 2013, and
had not filed the required information to allay the bureau’s concerns.
When
word about the letter got out, the ever-ready machine of Internet
journalism whirred quickly to life. Defenders of the genetic research
firm argued that the information, if used properly and with a
physician’s supervision, is not only...
Related Articles
By Ali Breland, The Atlantic | 08.20.2024
“Joining us now is Steve Sailer, who I find to be incredibly interesting, and one of the most talented noticers,” Charlie Kirk said on his internet show in October. Kirk, the 30-year-old founder of Turning Point USA, a right-wing...
By Megan Agnew, The Times | 09.15.2024
Faith Hartley always wanted two girls — a blonde and a redhead. “I thought, I’ll have one that looks like me,” says Hartley, 35, smoothing her golden hair in the Los Angeles valley home she shares with her husband, Neil...
By Emily R. Klancher Merchant, Los Angeles Review of Books | 08.22.2024
IN THE Operation Varsity Blues scandal of 2019, 50 wealthy parents were charged with trying to get their children into elite universities through fraudulent means. The story dramatically demonstrated the lengths to which some parents will go to ensure their...
By Julia Brown, The Conversation | 08.16.2024
With their primary goal to advance scientific knowledge, most scientists are not trained or incentivized to think through the societal implications of the technologies they are developing. Even in genomic medicine, which is geared toward benefiting future patients, time and...